REGN EBITDA | REGENERON PHARMACEUTICALS, INC.

REGENERON PHARMACEUTICALS, INC. (REGN) EBITDA

2026-06-30: Basis Reported; EBITDA $1.42B*; Operating income $1.29B; Depreciation and amortization $123.70M*.
2026-03-31: Basis Reported; EBITDA $766.10M*; Operating income $642.90M; Depreciation and amortization $123.20M.
2025-09-30: Basis Reported; EBITDA $1.16B*; Operating income $1.03B; Depreciation and amortization $136.70M*.
2025-06-30: Basis Reported; EBITDA $1.21B*; Operating income $1.08B; Depreciation and amortization $135.10M*.

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$1.42B*	$1.29B	$123.70M*	$4.29B	33.03%*	(m)	$813.00M*	(m)	$1.63B	$662.10M	$230.90M
2026-03-31	Reported	$766.10M*	$642.90M	$123.20M	$3.61B	21.25%*	(m)	$1.08B	(m)	$1.54B	$647.70M	$104.00M
2025-09-30	Reported	$1.16B*	$1.03B	$136.70M*	$3.75B	30.99%*	(m)	$1.62B*	(m)	$1.48B	$657.80M	$303.30M
2025-06-30	Reported	$1.21B*	$1.08B	$135.10M*	$3.68B	33.04%*	(m)	$1.14B*	(m)	$1.42B	$634.20M	$127.10M
2025-03-31	Reported	$718.60M*	$591.70M	$126.90M	$3.03B	23.73%*	(m)	$1.05B	(m)	$1.33B	$633.00M	$96.30M
2024-09-30	Reported	$1.30B*	$1.18B	$121.70M*	$3.72B	34.97%*	(m)	$1.29B*	(m)	$1.27B	$714.40M	$152.40M
2024-06-30	Reported	$1.19B*	$1.07B	$120.70M*	$3.55B	33.56%*	(m)	$354.00M*	(m)	$1.20B	$758.80M	$195.80M
2024-03-31	Reported	$865.50M*	$751.40M	$114.10M	$3.15B	27.52%*	(m)	$1.51B	(m)	$1.25B	$689.00M	-$21.30M
2023-09-30	Reported	$1.22B*	$1.11B	$105.40M*	$3.36B	36.17%*	(m)	$1.11B*	(m)	$1.08B	$640.50M	$103.00M
2023-06-30	Reported	$1.12B*	$1.02B	$103.10M*	$3.16B	35.45%*	(m)	$1.02B*	(m)	$1.09B	$652.00M	$114.50M
2023-03-31	Reported	$1.05B*	$946.70M	$99.50M	$3.16B	33.09%*	(m)	$1.37B	(m)	$1.10B	$601.10M	$40.20M
2022-09-30	Reported	$1.32B*	$1.22B	$92.60M*	$2.94B	44.83%*	(m)	$628.90M*	(m)	$911.30M	$529.10M	$194.10M
2022-06-30	Reported	$1.18B*	$1.11B	$74.40M*	$2.86B	41.45%*	(m)	$564.40M*	(m)	$794.30M	$476.30M	$111.10M
2022-03-31	Reported	$1.33B*	$1.26B	$74.30M	$2.97B	44.95%*	(m)	$2.10B	(m)	$843.80M	$450.00M	$87.60M
2021-09-30	Reported	$1.92B*	$1.85B	$73.20M*	$3.45B	55.62%*	(m)	$3.41B*	(m)	$665.40M	$445.00M	$184.40M
2021-06-30	Reported	$3.42B*	$3.35B	$71.10M*	$5.14B	66.52%*	(m)	$626.70M*	(m)	$714.20M	$414.70M	$653.90M
2021-03-31	Reported	$1.18B*	$1.11B	$67.40M	$2.53B	46.67%*	(m)	$668.50M	(m)	$742.90M	$405.60M	$137.80M
2020-09-30	Reported	$1.11B*	$1.05B	$59.30M*	$2.29B	48.49%*	(m)	-$254.30M*	(m)	$684.60M	$326.90M	$156.20M
2020-06-30	Reported	$715.20M*	$656.40M	$58.80M*	$1.95B	36.64%*	(m)	$943.40M*	(m)	$722.00M	$348.30M	$21.60M
2020-03-31	Reported	$756.20M*	$700.10M	$56.10M	$1.83B	41.36%*	(m)	$698.00M	(m)	$583.90M	$367.30M	$44.00M
2019-09-30	Reported	$791.40M*	$738.50M	$52.90M*	$1.74B	45.39%*	(m)	$557.30M*	(m)	$526.00M	$304.40M	$98.90M
2019-06-30	Reported	$367.70M*	$315.60M	$52.10M*	$1.58B	23.30%*	(m)	$188.30M*	(m)	$885.50M	$294.60M	$31.60M
2019-03-31	Reported	$531.00M*	$480.00M	$51.00M	$1.37B	38.69%*	(m)	$897.00M	(m)	$486.10M	$291.10M	$85.00M
2018-09-30	Reported	$662.30M*	$626.90M	$35.40M*	$1.66B	39.81%*	(m)	$452.90M*	(m)	$557.00M	$369.20M	$41.20M
2018-06-30	Reported	$655.80M*	$622.20M	$33.60M*	$1.61B	40.78%*	(m)	$394.60M*	(m)	$529.30M	$364.80M	$104.70M
2018-03-31	Reported	$603.60M*	$567.20M	$36.40M	$1.51B	39.93%*	(m)	$618.80M	(m)	$498.60M	$330.80M	$107.40M
2017-09-30	Reported	$597.64M*	$559.93M	$37.72M*	$1.50B	39.82%*	(m)	$414.83M*	(m)	$529.75M	$306.77M	$177.29M
2017-06-30	Reported	$585.44M*	$550.31M	$35.13M*	$1.47B	39.82%*	(m)	-$30.57M*	(m)	$509.98M	$306.91M	$138.11M
2017-03-31	Reported	$468.66M*	$430.54M	$38.12M	$1.32B	35.53%*	(m)	$355.90M	(m)	$507.44M	$296.85M	$183.36M
2016-09-30	Reported	$390.64M*	$362.80M	$27.84M*	(m)	(m)	(m)	$651.03M*	(m)	$543.05M	$270.05M	$101.08M
2016-06-30	Reported	$316.66M*	$291.63M	$25.03M*	(m)	(m)	(m)	$399.50M*	(m)	$559.93M	$292.04M	$96.04M
2016-03-31	Reported	$352.29M*	$329.31M	$22.98M	(m)	(m)	(m)	$44.99M	(m)	$470.11M	$289.68M	$148.77M
2015-09-30	Reported	$413.10M*	$392.42M	$20.67M*	(m)	(m)	(m)	$892.85M*	(m)	$425.92M	$209.99M	$182.89M
2015-06-30	Reported	$360.16M*	$344.86M	$15.30M*	(m)	(m)	(m)	$257.83M*	(m)	$390.33M	$174.59M	$133.35M
2015-03-31	Reported	$299.58M*	$283.55M	$16.03M	(m)	(m)	(m)	-$101.73M	(m)	$343.11M	$158.99M	$200.50M
2014-12-31	Reported	(m)	$215.80M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$175.31M	$99.63M
2014-09-30	Reported	$202.47M*	$188.46M	$14.01M*	(m)	(m)	(m)	$164.32M*	(m)	$337.73M	$144.00M	$98.45M
2014-06-30	Reported	$241.11M*	$228.09M	$13.02M*	(m)	(m)	(m)	$336.41M*	(m)	$294.50M	$96.73M	$112.45M
2014-03-31	Reported	$203.09M*	$191.56M	$11.53M	(m)	(m)	(m)	$53.53M	(m)	$287.38M	$103.23M	$112.58M
2013-09-30	Reported	$247.60M*	$236.80M	$10.80M*	(m)	(m)	(m)	$92.45M*	(m)	$224.04M	$97.61M	$84.38M
2013-06-30	Reported	$167.81M*	$158.10M	$9.70M*	(m)	(m)	(m)	$128.16M*	(m)	$187.46M	$72.46M	$60.32M
2013-03-31	Reported	$162.46M*	$153.05M	$9.41M	(m)	(m)	(m)	$86.25M	(m)	$180.30M	$77.26M	$42.96M
2012-09-30	Reported	$211.69M*	$202.36M	$9.33M*	(m)	(m)	(m)	-$2.38M*	(m)	$158.29M	$46.88M	(m)
2012-06-30	Reported	$96.89M*	$87.48M	$9.42M*	(m)	(m)	(m)	-$78.38M*	(m)	$147.37M	$47.70M	$0.00
2012-03-31	Reported	$30.62M*	$22.20M	$8.42M	(m)	(m)	(m)	-$87.04M	(m)	$138.86M	$58.43M	(m)
2011-09-30	Reported	-$50.18M*	-$58.46M	$8.28M*	(m)	(m)	(m)	-$46.73M*	(m)	$127.92M	$32.92M	$562.00K
2011-06-30	Reported	-$52.42M*	-$60.32M	$7.90M*	(m)	(m)	(m)	-$34.05M*	(m)	$143.15M	$24.59M	-$863.00K
2011-03-31	Reported	-$34.00M*	-$40.98M	$6.98M	(m)	(m)	(m)	-$10.58M	(m)	$129.39M	$23.41M	-$216.00K
2010-09-30	Reported	-$27.20M*	-$32.09M	$4.89M*	(m)	(m)	(m)	$161.50M*	(m)	$122.04M	$15.66M	$0.00
2010-06-30	Reported	-$19.20M*	-$23.72M	$4.52M*	(m)	(m)	(m)	-$11.85M*	(m)	$124.53M	$14.68M	$0.00
2010-03-31	Reported	-$24.69M*	-$28.88M	$4.18M	(m)	(m)	(m)	-$9.58M	(m)	$117.47M	$14.22M	$0.00
2009-09-30	Reported	$2.30M*	-$1.29M	$3.59M*	(m)	(m)	(m)	-$9.82M*	(m)	$105.43M	$12.84M	(m)
2009-06-30	Reported	(m)	-$16.27M	(m)	(m)	(m)	(m)	(m)	(m)	$94.23M	$11.63M	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$4.12B*	$3.58B	$543.70M	$14.34B	28.74%*	(m)	$4.98B	(m)	$5.85B	$2.70B	$725.80M
2024-12-31	Reported	$4.47B*	$3.99B	$482.90M	$14.20B	31.50%*	(m)	$4.42B	(m)	$5.13B	$2.95B	$367.30M
2023-12-31	Reported	$4.47B*	$4.05B	$421.00M	$13.12B	34.06%*	(m)	$4.59B	(m)	$4.44B	$2.63B	$245.70M
2022-12-31	Reported	$5.08B*	$4.74B	$341.40M	$12.17B	41.73%*	(m)	$5.01B	(m)	$3.59B	$2.12B	$520.40M
2021-12-31	Reported	$9.23B*	$8.95B	$286.20M	$16.07B	57.45%*	(m)	$7.08B	(m)	$2.86B	$1.82B	$1.25B
2020-12-31	Reported	$3.81B*	$3.58B	$235.90M	$8.50B	44.87%*	(m)	$2.62B	(m)	$2.65B	$1.35B	$297.20M
2019-12-31	Reported	$2.42B*	$2.21B	$210.30M	$6.56B	36.91%*	(m)	$2.43B	$402.80M	$2.45B	$1.34B	$313.30M
2018-12-31	Reported	$2.68B*	$2.53B	$148.20M	$5.15B	52.13%*	(m)	$2.20B	$237.50M	$1.47B	$1.13B	$109.10M
2017-12-31	Reported	$2.23B*	$2.08B	$145.50M	$5.87B	37.89%*	(m)	$1.31B	(m)	$2.08B	$1.32B	$880.00M
2016-12-31	Reported	$1.44B*	$1.33B	$104.70M	$4.86B	29.53%*	(m)	$1.49B	(m)	$2.05B	$1.18B	$434.30M
2015-12-31	Reported	$1.33B*	$1.25B	$74.91M	(m)	(m)	(m)	$1.33B	(m)	$1.62B	$838.53M	$589.04M
2015-09-30	Rolling	(m)	$1.24B*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$718.88M*	$616.37M*
2015-06-30	Rolling	(m)	$1.03B*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$652.89M*	$531.93M*
2015-03-31	Rolling	(m)	$915.91M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$575.03M*	$511.03M*
2014-12-31	Reported	$876.61M*	$823.92M	$52.69M	(m)	(m)	(m)	$752.43M	(m)	$1.27B	$519.27M	$423.11M
2014-12-31	Rolling	(m)	$823.92M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$519.27M*	$423.11M*
2013-12-31	Reported	$784.25M*	$743.05M	$41.20M	(m)	(m)	(m)	$588.60M	(m)	$859.95M	$346.39M	$282.64M
2012-12-31	Reported	$494.65M*	$457.71M	$36.94M	(m)	(m)	(m)	-$74.61M	(m)	$625.55M	$210.75M	-$335.85M
2011-12-31	Reported	-$174.08M*	-$205.16M	$31.08M	(m)	(m)	(m)	-$141.68M	(m)	$529.51M	$117.26M	-$1.13M
2010-12-31	Reported	-$77.78M*	-$97.47M	$19.69M	(m)	(m)	(m)	$99.22M	(m)	$489.25M	$65.20M	$0.00
2009-12-31	Reported	-$59.90M*	-$74.10M	$14.20M	(m)	(m)	(m)	-$69.94M	(m)	$398.76M	$52.92M	-$4.12M
2008-12-31	Reported	-$74.96M*	-$86.25M	$11.29M	(m)	(m)	(m)	-$89.09M	(m)	$274.90M	$48.88M	$2.35M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64
Viatris Inc (VTRS)	United States	$20.008B	-0.00
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
Jazz Pharmaceuticals plc (JAZZ)		$15.333B	16.07